Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.

Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Cancer Sci. 2018 Oct 5. doi: 10.1111/cas.13820. [Epub ahead of print]

2.

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade.

Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I.

Oncotarget. 2018 Jul 17;9(55):30587-30593. doi: 10.18632/oncotarget.25743. eCollection 2018 Jul 17.

3.

Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer.

Kimura S, Harada T, Ijichi K, Tanaka K, Liu R, Shibahara D, Kawano Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Jun;120:98-107. doi: 10.1016/j.lungcan.2018.04.005. Epub 2018 Apr 5.

PMID:
29748024
4.

Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.

Shibahara D, Tanaka K, Iwama E, Kubo N, Ota K, Azuma K, Harada T, Fujita J, Nakanishi Y, Okamoto I.

J Thorac Oncol. 2018 Jul;13(7):926-937. doi: 10.1016/j.jtho.2018.03.012. Epub 2018 Mar 27.

PMID:
29596910
5.

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.

Yoneshima Y, Ijichi K, Anai S, Ota K, Otsubo K, Iwama E, Tanaka K, Oda Y, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Apr;118:36-40. doi: 10.1016/j.lungcan.2018.01.024. Epub 2018 Feb 2.

PMID:
29572000
6.

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.

Iwama E, Nakanishi Y, Okamoto I.

Expert Rev Anticancer Ther. 2018 Mar;18(3):267-276. doi: 10.1080/14737140.2018.1432356. Epub 2018 Jan 27.

PMID:
29363369
7.

CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.

Kawano Y, Iwama E, Tsuchihashi K, Shibahara D, Harada T, Tanaka K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

Lung Cancer. 2017 Nov;113:72-78. doi: 10.1016/j.lungcan.2017.09.008. Epub 2017 Sep 14.

PMID:
29110853
8.

Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups.

Yabuuchi H, Kawanami S, Iwama E, Okamoto I, Kamitani T, Sagiyama K, Yamasaki Y, Honda H.

Radiology. 2018 Feb;286(2):685-695. doi: 10.1148/radiol.2017162204. Epub 2017 Oct 23.

PMID:
29059037
9.

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations.

Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, Morinaga R, Wataya H, Fujii A, Nakagaki N, Tsuruta N, Takeshita M, Iwama E, Harada T, Nakanishi Y, Okamoto I.

Oncotarget. 2017 Jul 12;8(40):68123-68130. doi: 10.18632/oncotarget.19243. eCollection 2017 Sep 15.

10.

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.

Otsubo K, Nosaki K, Imamura CK, Ogata H, Fujita A, Sakata S, Hirai F, Toyokawa G, Iwama E, Harada T, Seto T, Takenoyama M, Ozeki T, Mushiroda T, Inada M, Kishimoto J, Tsuchihashi K, Suina K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

Cancer Sci. 2017 Sep;108(9):1843-1849. doi: 10.1111/cas.13309. Epub 2017 Jul 26.

11.

Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.

Hidaka N, Iwama E, Kubo N, Harada T, Miyawaki K, Tanaka K, Okamoto I, Baba E, Akashi K, Sasaki H, Nakanishi Y.

Lung Cancer. 2017 Jun;108:75-82. doi: 10.1016/j.lungcan.2017.02.019. Epub 2017 Mar 1.

PMID:
28625653
12.

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.

Ogata H, Yamamoto Y, Harada T, Nakanishi Y, Okamoto I, Iwama E, Kato K, Oda Y.

J Thorac Oncol. 2017 May;12(5):e46-e47. doi: 10.1016/j.jtho.2016.12.023. No abstract available.

13.

Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

Ogata H, Okamoto I, Yoshimoto G, Obara T, Ijichi K, Iwama E, Harada T, Akashi K, Nakanishi Y.

Respir Investig. 2017 Mar;55(2):181-183. doi: 10.1016/j.resinv.2016.12.002. Epub 2017 Jan 12.

PMID:
28274536
14.

Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401).

Iwama E, Goto Y, Murakami H, Harada T, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Okazaki A, Akamatsu H, Morinaga R, Ushijima S, Shimose T, Tokunaga S, Hamada A, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I.

J Thorac Oncol. 2017 Jul;12(7):1161-1166. doi: 10.1016/j.jtho.2017.02.012. Epub 2017 Feb 24.

15.

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.

Iwama E, Sakai K, Azuma K, Harada T, Harada D, Nosaki K, Hotta K, Ohyanagi F, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Ann Oncol. 2017 Jan 1;28(1):136-141. doi: 10.1093/annonc/mdw531.

PMID:
28177428
16.

Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.

Sakata S, Saeki S, Okamoto I, Otsubo K, Komiya K, Morinaga R, Yoneshima Y, Koga Y, Enokizu A, Kishi H, Hirosako S, Yamaguchi E, Aragane N, Fujii S, Harada T, Iwama E, Semba H, Nakanishi Y, Kohrogi H.

Lung Cancer. 2016 Sep;99:41-5. doi: 10.1016/j.lungcan.2016.06.009. Epub 2016 Jun 14.

PMID:
27565912
17.

Ultrafast Nanocrystalline-TiO2 (B)/Carbon Nanotube Hyperdispersion Prepared via Combined Ultracentrifugation and Hydrothermal Treatments for Hybrid Supercapacitors.

Naoi K, Kurita T, Abe M, Furuhashi T, Abe Y, Okazaki K, Miyamoto J, Iwama E, Aoyagi S, Naoi W, Simon P.

Adv Mater. 2016 Aug;28(31):6751-7. doi: 10.1002/adma.201600798. Epub 2016 May 27.

PMID:
27229372
18.

Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae.

Iwama E, Okamoto I, Yabuuchi H, Takayama K, Harada T, Matsuo Y, Tokunaga S, Baba E, Nakanishi Y.

J Thorac Oncol. 2016 Sep;11(9):1586-90. doi: 10.1016/j.jtho.2016.04.024. Epub 2016 May 7.

19.

Enhanced Electrochemical Performance of Ultracentrifugation-Derived nc-Li3VO4/MWCNT Composites for Hybrid Supercapacitors.

Iwama E, Kawabata N, Nishio N, Kisu K, Miyamoto J, Naoi W, Rozier P, Simon P, Naoi K.

ACS Nano. 2016 May 24;10(5):5398-404. doi: 10.1021/acsnano.6b01617. Epub 2016 May 9.

PMID:
27158830
20.

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot.

Iwama E, Fujimura T, Kusakari Y, Haga T, Aiba S.

Case Rep Dermatol. 2015 Oct 30;7(3):322-7. doi: 10.1159/000441601. eCollection 2015 Sep-Dec.

21.

[II. Development and Future Prospects of the Third-Generation EGFR-Tyrosine Kinase Inhibitor].

Sakata S, Iwama E, Okamoto I.

Gan To Kagaku Ryoho. 2015 Aug;42(8):935-9. Japanese. No abstract available.

PMID:
26353390
22.

Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.

Yamamoto Y, Okamoto I, Otsubo K, Iwama E, Hamada N, Harada T, Takayama K, Nakanishi Y.

Invest New Drugs. 2015 Oct;33(5):1148-50. doi: 10.1007/s10637-015-0284-9. Epub 2015 Sep 4.

PMID:
26334220
23.

Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer.

Ikesue H, Watanabe H, Hirano M, Chikamori A, Suetsugu K, Ryokai Y, Egashira N, Yamada T, Ikeda M, Iwama E, Harada T, Takayama K, Nakanishi Y, Masuda S.

Biol Pharm Bull. 2015;38(8):1192-8. doi: 10.1248/bpb.b15-00162.

24.

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.

Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I.

Clin Cancer Res. 2015 Sep 1;21(17):4014-21. doi: 10.1158/1078-0432.CCR-15-0016. Epub 2015 May 27.

25.

Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR.

Iwama E, Takayama K, Harada T, Okamoto I, Ookubo F, Kishimoto J, Baba E, Oda Y, Nakanishi Y.

Oncotarget. 2015 Aug 21;6(24):20466-73.

26.

Successful treatment with alectinib after crizotinib-induced esophageal ulceration.

Yoneshima Y, Okamoto I, Takano T, Enokizu A, Iwama E, Harada T, Takayama K, Nakanishi Y.

Lung Cancer. 2015 Jun;88(3):349-51. doi: 10.1016/j.lungcan.2015.03.012. Epub 2015 Mar 20.

PMID:
25837798
27.

Merkel Cell Carcinoma Concomitant with Invasive Bowen's Disease: Immunohistochemical Investigation of Tumor-Infiltrating Leukocytes.

Tono H, Fujimura T, Iwama E, Kusakari Y, Furudate S, Kambayashi Y, Haga T, Hashimoto A, Aiba S.

Case Rep Dermatol. 2015 Jan 14;7(1):1-6. doi: 10.1159/000371732. eCollection 2015 Jan-Apr.

28.

Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.

Fujii A, Harada T, Iwama E, Ota K, Furuyama K, Ijichi K, Okamoto T, Okamoto I, Takayama K, Nakanishi Y.

Cancer Genet. 2015 May;208(5):271-8. doi: 10.1016/j.cancergen.2014.12.005. Epub 2015 Jan 6.

PMID:
25682017
29.

Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.

Li H, Wang S, Takayama K, Harada T, Okamoto I, Iwama E, Fujii A, Ota K, Hidaka N, Kawano Y, Nakanishi Y.

Lung Cancer. 2015 Apr;88(1):1-8. doi: 10.1016/j.lungcan.2015.01.017. Epub 2015 Jan 25.

30.

PICT1 expression is a poor prognostic factor in non-small cell lung cancer.

Okamura K, Takayama K, Kawahara K, Harada T, Nishio M, Otsubo K, Ijichi K, Kohno M, Iwama E, Fujii A, Ota K, Koga T, Okamoto T, Suzuki A, Nakanishi Y.

Oncoscience. 2014 May 25;1(5):375-82. eCollection 2014.

31.

Acquired Idiopathic Generalized Anhidrosis: An Immunohistopathological Investigation of Peri-glands Infiltrated with Immunoreactive Cells.

Iwama E, Fujimura T, Tanita K, Ishibashi M, Watabe A, Aiba S.

Acta Derm Venereol. 2015 Jul;95(6):743-4. doi: 10.2340/00015555-2034. No abstract available.

32.

Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement.

Yoneshima Y, Okamoto I, Arimura-Omori M, Kimura S, Hidaka-Fujimoto N, Iwama E, Harada T, Takayama K, Nakanishi Y.

Invest New Drugs. 2015 Apr;33(2):510-2. doi: 10.1007/s10637-014-0195-1. Epub 2014 Nov 30.

PMID:
25433426
33.

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.

Li H, Takayama K, Wang S, Shiraishi Y, Gotanda K, Harada T, Furuyama K, Iwama E, Ieiri I, Okamoto I, Nakanishi Y.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1297-305. doi: 10.1007/s00280-014-2610-x. Epub 2014 Oct 26.

34.

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.

Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I.

Ann Oncol. 2014 Oct;25(10):1935-40. doi: 10.1093/annonc/mdu242. Epub 2014 Jul 9.

PMID:
25009014
35.

[Personalized medicine in non-small-cell carcinoma].

Iwama E, Takayama K, Baba E, Nakanishi Y.

Fukuoka Igaku Zasshi. 2014 Mar;105(3):57-66. Review. Japanese. No abstract available.

PMID:
25000657
36.

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer.

Iwama E, Okamoto I, Harada T, Takayama K, Nakanishi Y.

Onco Targets Ther. 2014 Mar 5;7:375-85. doi: 10.2147/OTT.S38868. eCollection 2014. Review.

37.

Progress of the conversion reaction of Mn3O4 particles as a function of the depth of discharge.

Yonekura D, Iwama E, Ota N, Muramatsu M, Saito M, Orikasa Y, Naoi W, Naoi K.

Phys Chem Chem Phys. 2014 Apr 7;16(13):6027-32. doi: 10.1039/c4cp00334a.

PMID:
24554035
38.

Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.

Nakano M, Kusaba H, Makiyama A, Ariyama H, Arita S, Oda H, Esaki T, Takayoshi K, Uchino K, Tamura S, Kumagai H, Iwama E, Shirakawa T, Mitsugi K, Takaishi S, Akashi K, Baba E.

Anticancer Res. 2014 Jan;34(1):215-20.

PMID:
24403465
39.

Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.

Furuyama K, Harada T, Iwama E, Shiraishi Y, Okamura K, Ijichi K, Fujii A, Ota K, Wang S, Li H, Takayama K, Giaccone G, Nakanishi Y.

Cancer Sci. 2013 May;104(5):584-9. doi: 10.1111/cas.12125. Epub 2013 Mar 28.

40.

Cancer-related PRUNE2 protein is associated with nucleotides and is highly expressed in mature nerve tissues.

Iwama E, Tsuchimoto D, Iyama T, Sakumi K, Nakagawara A, Takayama K, Nakanishi Y, Nakabeppu Y.

J Mol Neurosci. 2011 Jun;44(2):103-14. doi: 10.1007/s12031-010-9490-2. Epub 2011 Jan 14.

PMID:
21234814

Supplemental Content

Support Center